Skip to main content
. 2021 Mar 29;9(3):335–344. doi: 10.14218/JCTH.2020.00164

Fig. 4. Pooled OR of virological response in tenofovir alafenamide fumarate (TAF)-treated vs. TDF-treated CHB patients after 48 weeks of treatment.

Fig. 4

CHB, chronic hepatitis B; OR, odds ratio; TAF, Tenofovir alafenamide fumarate; TDF, tenofovir disoproxil fumarate.